Angelita Rebamontan Domingo Sells 998 Shares of Pro-Dex (NASDAQ:PDEX) Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Angelita Rebamontan Domingo sold 998 shares of the firm’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $47.24, for a total value of $47,145.52. Following the completion of the transaction, the director directly owned 18,779 shares in the company, valued at $887,119.96. The trade was a 5.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Pro-Dex Stock Performance

Shares of Pro-Dex stock traded down $3.29 during trading hours on Tuesday, reaching $58.26. 38,447 shares of the stock traded hands, compared to its average volume of 40,368. The company has a 50 day moving average price of $62.13 and a 200 day moving average price of $50.82. The firm has a market capitalization of $186.02 million, a price-to-earnings ratio of 16.09 and a beta of 0.01. Pro-Dex, Inc. has a one year low of $23.47 and a one year high of $68.99. The company has a quick ratio of 2.14, a current ratio of 3.67 and a debt-to-equity ratio of 0.32.

Pro-Dex (NASDAQ:PDEX) last issued its quarterly earnings data on Thursday, April 30th. The medical instruments supplier reported $1.20 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.58. The firm had revenue of $19.95 million for the quarter, compared to analysts’ expectations of $17.90 million. Pro-Dex had a net margin of 16.08% and a return on equity of 22.78%. On average, equities research analysts expect that Pro-Dex, Inc. will post 3.16 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Weiss Ratings upgraded shares of Pro-Dex from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, July 1st. Zacks Research upgraded Pro-Dex to a “hold” rating in a research note on Tuesday, May 19th. Ascendiant Capital Markets raised their target price on Pro-Dex from $56.00 to $70.00 and gave the stock a “buy” rating in a report on Tuesday, May 12th. Finally, Wall Street Zen upgraded Pro-Dex from a “hold” rating to a “buy” rating in a research report on Saturday, June 13th. Two research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $70.00.

Institutional Trading of Pro-Dex

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Punch & Associates Investment Management Inc. raised its position in shares of Pro-Dex by 23.4% during the 4th quarter. Punch & Associates Investment Management Inc. now owns 60,000 shares of the medical instruments supplier’s stock valued at $2,309,000 after purchasing an additional 11,392 shares during the period. JPMorgan Chase & Co. boosted its holdings in Pro-Dex by 67.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 35,877 shares of the medical instruments supplier’s stock worth $1,566,000 after buying an additional 14,479 shares during the period. Geode Capital Management LLC increased its stake in Pro-Dex by 93.2% in the 2nd quarter. Geode Capital Management LLC now owns 51,668 shares of the medical instruments supplier’s stock worth $2,255,000 after buying an additional 24,927 shares in the last quarter. Morgan Dempsey Capital Management LLC increased its stake in Pro-Dex by 33.1% in the 3rd quarter. Morgan Dempsey Capital Management LLC now owns 5,469 shares of the medical instruments supplier’s stock worth $185,000 after buying an additional 1,360 shares in the last quarter. Finally, Osaic Holdings Inc. increased its stake in Pro-Dex by 44.8% in the 4th quarter. Osaic Holdings Inc. now owns 11,434 shares of the medical instruments supplier’s stock worth $440,000 after buying an additional 3,540 shares in the last quarter. 15.28% of the stock is owned by hedge funds and other institutional investors.

About Pro-Dex

Pro-Dex, Inc is a designer and manufacturer of precision drive systems and fluid management products serving the dental, medical, industrial and energy markets. The company specializes in high-speed, brushless micromotors and controllers, as well as pneumatic and fluid control devices, providing both standard and custom-engineered solutions for original equipment manufacturers.

Its product portfolio includes high-speed dental handpieces, turbine systems, rotary and reciprocating micro-drives, along with integrated fluid delivery systems.